N-(3-ethylsulfanyl-1H-1,2,4-triazol-5-yl)-1-methyl-5-[methyl-(4-methylphenyl)sulfonylamino]pyrazole-4-carboxamide
C17H21N7O3S2 — CID 108810960
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-(3-ethylsulfanyl-1H-1,2,4-triazol-5-yl)-1-methyl-5-[methyl-(4-methylphenyl)sulfonylamino]pyrazole-4-carboxamide
N-(3-ethylsulfanyl-1H-1,2,4-triazol-5-yl)-1-methyl-5-[methyl-(4-methylphenyl)sulfonylamino]pyrazole-4-carboxamide (PubChem CID 108810960) has the molecular formula C17H21N7O3S2 and a molecular weight of 435.54 g/mol. Its IUPAC name is N-(3-ethylsulfanyl-1H-1,2,4-triazol-5-yl)-1-methyl-5-[methyl-(4-methylphenyl)sulfonylamino]pyrazole-4-carboxamide.
Molecular Properties
| Compound Name | N-(3-ethylsulfanyl-1H-1,2,4-triazol-5-yl)-1-methyl-5-[methyl-(4-methylphenyl)sulfonylamino]pyrazole-4-carboxamide |
|---|---|
| PubChem CID | 108810960 |
| Molecular Formula | C17H21N7O3S2 |
| Molecular Weight | 435.54 g/mol |
| Exact Mass | 435.11 |
| IUPAC Name | N-(3-ethylsulfanyl-1H-1,2,4-triazol-5-yl)-1-methyl-5-[methyl-(4-methylphenyl)sulfonylamino]pyrazole-4-carboxamide |
| SMILES | CCSc1n[nH]c(NC(=O)c2cnn(C)c2N(C)S(=O)(=O)c2ccc(C)cc2)n1 |
| InChI | InChI=1S/C17H21N7O3S2/c1-5-28-17-20-16(21-22-17)19-14(25)13-10-18-23(3)15(13)24(4)29(26,27)12-8-6-11(2)7-9-12/h6-10H,5H2,1-4H3,(H2,19,20,21,22,25) |
| InChIKey | SWDYAPKQLUWLPQ-UHFFFAOYSA-N |
| XLogP | 2.04 |
| TPSA | 125.87 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 435.54 |
| LogP ≤ 5 | 2.04 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 108810960 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.